EVAX Fundamental Analysis - EVAXION A/S

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to EVAX. EVAX was compared to 549 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EVAX has reported negative net income.

EVAX had a negative operating cash flow in the past year.

EVAX had negative earnings in each of the past 5 years.

In the past 5 years EVAX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -84.65%, EVAX is not doing good in the industry: 71.58% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-84.65%
ROE	N/A
ROIC	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for EVAX has been increased compared to 1 year ago.

EVAX has less shares outstanding than it did 5 years ago.

EVAX has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.75, we must say that EVAX is in the distress zone and has some risk of bankruptcy.

EVAX has a Altman-Z score (-3.75) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.75

ROIC/WACCN/A

WACC5.26%

2.3 Liquidity

EVAX has a Current Ratio of 2.01. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.

EVAX's Current ratio of 2.01 is on the low side compared to the rest of the industry. EVAX is outperformed by 75.05% of its industry peers.

EVAX has a Quick Ratio of 2.01. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.01, EVAX is doing worse than 73.41% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.01
Quick Ratio	2.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.02% over the past year.

The Revenue has grown by 4480.82% in the past year. This is a very strong growth!

EPS 1Y (TTM)76.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%96.67%

Revenue 1Y (TTM)4480.82%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-75.97%

3.2 Future

EVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.24% yearly.

Based on estimates for the next years, EVAX will show a very strong growth in Revenue. The Revenue will grow by 61.85% on average per year.

EPS Next Y20.4%

EPS Next 2Y15.55%

EPS Next 3Y26.37%

EPS Next 5Y15.24%

Revenue Next Year-100%

Revenue Next 2Y0.95%

Revenue Next 3Y59.75%

Revenue Next 5Y61.85%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

EVAX's earnings are expected to grow with 26.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.55%

EPS Next 3Y26.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EVAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVAXION A/S

NASDAQ:EVAX (8/20/2025, 8:00:01 PM)

2.95

-0.09 (-2.96%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)10-29 2025-10-29

Inst Owners2.16%

Inst Owner Change-15.2%

Ins Owners0.68%

Ins Owner ChangeN/A

Market Cap18.63M

Analysts82.5

Price Target38.76 (1213.9%)

Short Float %2.43%

Short Ratio1.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)48.94%

Min EPS beat(2)11.56%

Max EPS beat(2)86.32%

EPS beat(4)4

Avg EPS beat(4)80.18%

Min EPS beat(4)11.56%

Max EPS beat(4)152.99%

EPS beat(8)7

Avg EPS beat(8)40.41%

EPS beat(12)10

Avg EPS beat(12)32.21%

EPS beat(16)12

Avg EPS beat(16)23.88%

Revenue beat(2)1

Avg Revenue beat(2)42.12%

Min Revenue beat(2)-92.79%

Max Revenue beat(2)177.04%

Revenue beat(4)3

Avg Revenue beat(4)77.43%

Min Revenue beat(4)-92.79%

Max Revenue beat(4)190.35%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)19.06%

PT rev (3m)19.06%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)25.43%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)N/A

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.57
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-4.22

EYN/A

EPS(NY)-1.86

Fwd EYN/A

FCF(TTM)-2.05

FCFYN/A

OCF(TTM)-2.05

OCFYN/A

SpS0.53

BVpS-0.26

TBVpS-0.26

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-84.65%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.27

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	0%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.01
Quick Ratio	2.01
Altman-Z	-3.75

F-Score5

WACC5.26%

ROIC/WACCN/A

Cap/Depr(3y)21.76%

Cap/Depr(5y)127.17%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)76.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%96.67%

EPS Next Y20.4%

EPS Next 2Y15.55%

EPS Next 3Y26.37%

EPS Next 5Y15.24%

Revenue 1Y (TTM)4480.82%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-75.97%

Revenue Next Year-100%

Revenue Next 2Y0.95%

Revenue Next 3Y59.75%

Revenue Next 5Y61.85%

EBIT growth 1Y33.63%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y27.21%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y26.86%

OCF growth 3YN/A

OCF growth 5YN/A

EVAXION A/S (EVAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens